Hereditary Prostate Cancer Genetic Testing

About this condition

Hereditary Prostate Cancer

Hereditary prostate cancer encompasses multiple distinct genetic predisposition pathways. BRCA2 carriers face 3–8-fold increased prostate cancer risk, with significantly more aggressive disease. The HOXB13 G84E variant is far more penetrant — conferring up to a 20-fold increased risk of hereditary prostate cancer, particularly among men of European ancestry. ATM pathogenic variants increase risk approximately 2–3-fold, with additional pancreatic cancer risk implications. All three genes function in DNA damage response: BRCA2 and ATM mediate DNA repair signaling; HOXB13 is a transcription factor essential for prostate development — each represents a distinct biological pathway to cancer susceptibility.

Hereditary prostate cancer accounts for 5–15% of prostate cancer cases overall, with significantly higher heritability estimates than most common cancers. HOXB13 G84E carriers represent 0.6–6.25% of hereditary prostate cancer cases in European populations. BRCA2 variants occur in 1.2–5.3% of hereditary prostate cancer families, ATM in 1.6–2.7%, and CHEK2 in 1.8–2.8%. Carriers tend to develop prostate cancer at younger ages (median age 55–60 vs. 65–70 in non-hereditary disease) with more aggressive Gleason scores and metastatic potential. Approximately 50% of men with a family history of prostate cancer carry a pathogenic variant in one of these genes.

Identifying the specific genetic cause has profound clinical implications. A BRCA2 finding qualifies men for PSA screening from age 40 and, if cancer develops, eligibility for PARP inhibitor therapy (olaparib) — a genotype-targeted therapy that produces durable responses in men with BRCA2-associated castration-resistant prostate cancer. An HOXB13 finding enables early screening and intensified family surveillance. All discoveries cascade to relatives: brothers can begin early screening to prevent or detect cancer earlier; sisters may carry the same variant and have breast/ovarian cancer risk (particularly BRCA2).

The three major hereditary prostate cancer genes operate through distinct biological mechanisms — BRCA2 and ATM in DNA repair signaling, HOXB13 in prostate development — each conferring different cancer aggressiveness and screening intervals.

Gene locus: BRCA2 (13q13.1), HOXB13 (17q21.32), ATM (11q22.3)

Prostate cancer has been historically under-tested genetically. BRCA2-only testing misses HOXB13 and ATM — genes that together account for significant hereditary disease.

Standard prostate panels often miss the culprit genes

Hereditary prostate cancer testing lags significantly behind breast and colorectal cancer testing. Many commercially available hereditary cancer panels were designed for breast/ovarian cancer and do not include HOXB13. Single-gene BRCA2 testing misses ATM and CHEK2 contributions. Across hereditary prostate cancer families, HOXB13 accounts for 0.6–6.25% of cases, BRCA2 for 1.2–5.3%, ATM for 1.6–2.7%, and CHEK2 for 1.8–2.8%. No single-gene or limited-panel approach captures the full genetic landscape. Whole genome sequencing reads all prostate cancer predisposition genes simultaneously.

A genetic finding opens targeted therapy and family prevention

BRCA2 carriers with metastatic prostate cancer are eligible for PARP inhibitor therapy (olaparib) — one of the few genotype-matched treatments in prostate cancer oncology. An HOXB13 G84E finding enables aggressive early PSA screening from age 40 in at-risk men. ATM findings inform pancreatic cancer surveillance for male carriers with family history. All findings trigger cascade testing: brothers can begin early PSA screening before cancer develops; sisters may carry the same variant and qualify for breast/ovarian cancer surveillance.

Your father and brother had aggressive prostate cancer. You're wondering if it's your inheritance. Before it develops, you could know.